Telisotuzumab vedotin (Teliso-V) gained FDA approval as a targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) with high c-Met overexpression, offering new hope.

While CTCs were identified regardless of disease stage, the current study identified large variations in the presence of CTCs between nonmetastatic and metastatic disease | Image Credit: Innovative Creation - stock.adobe.com

Flow Cytometry Can Reliably Identify CTC in Melanoma

By AJMC Contributor

May 14th 2025

The study, which used flow cytometry rather than molecular biology to identify circulating tumor cells (CTCs), found a significant positive correlation between the number of CTCs and the stage of disease.

Jack & Sheryl Morris Cancer Center | Image credit: RWJBarnabas Health

New Jersey’s First Freestanding Cancer Hospital Opens in New Brunswick

By Pearl Steinzor

May 14th 2025

RWJBarnabas Health and Rutgers Cancer Institute unveil the Jack & Sheryl Morris Cancer Center—1 of only 13 freestanding cancer hospitals in the US.

At 3 months, hospitalizations among patients enrolled in RSM were 19% lower vs historical controls. | Image Credit: Nuttapong punna - stock.adobe.com

Remote Symptom Monitoring Linked to Reduced Hospitalization Risk for Patients With Cancer

By Rose McNulty

May 14th 2025

Remote symptom monitoring in cancer care reduces hospitalizations, enhances value-based care, and supports diverse patient populations, according to new findings.

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

...

181 182 183 184 185

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions